

Emplicure takes up a loan in the amount of 9.0 MSEK

Emplicure AB (publ) has today entered into a loan agreement with a loan consortium through which the Company has taken up a loan in the amount of 9.0 MSEK. The loan consortium includes certain existing shareholders, including the board member Johan Wieslander. The purpose of the loan is to strengthen **the Company's** short-term working capital and to meet the requirement of going concern for the next twelve months.

The amount of the loan is 9.0 MSEK and the loan is subject to an monthly interest of 2 (two) percent. The loan shall be repaid no later than 31 March 2023, provided that the Company has not requested that the loan be converted. During the period from the payment of the loan and until 31 March 2023, the Company has a unilateral right to request that the whole loan amount or a part thereof (including accrued interest) be converted into new shares in the Company. The subscription price per share shall correspond to the volume-weighted average price of the Company's share on Nasdaq First North during a period of ten trading days before 31 March 2023 (or the earlier date on which conversion is requested by the Company). A conversion of the loan is conditioned upon that necessary corporate resolutions and approvals are obtained.

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on November 4, 2022 at 14.54 CET

For more information, please contact:

Håkan Engqvist
CEO
Phone: +46 (0)702 569 500
Email: hakan.engqvist@emplicure.com

Erik Magnusson
CFO
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Certified Adviser

Certified Adviser is Erik Penser Bank.



Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com